Aeglea BioTherapeutics Announces Grant of Inducement Awards
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
About Aeglea BioTheraeutics & Spyre Therapeutics
In June 2023, Aeglea completed the acquisition of Spyre Therapeutics and shifted its disease focus to inflammatory bowel disease (IBD). Spyre Therapeutics is a biotechnology company advancing a robust pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD. Spun out of Paragon Therapeutics in 2023, Spyre was founded by
For more information, please visit http://aeglea.com or www.spyretx.com.
Follow Aeglea BioTherapeutics on social media: @Aegleabio and LinkedIn.
Follow Spyre Therapeutics on social media: @spyretx and LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-announces-grant-of-inducement-awards-301858687.html
SOURCE Aeglea BioTherapeutics, Inc.
